Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened

Pharvaris (NASDAQ:PHVS)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $18.74, but opened at $18.18. Pharvaris shares last traded at $17.89, with a volume of 36,789 shares traded.

Pharvaris Stock Up 0.0 %

The firm has a market capitalization of $942.47 million, a price-to-earnings ratio of -6.44 and a beta of -3.06. The stock has a 50-day moving average price of $19.28 and a 200 day moving average price of $19.38.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Barclays PLC acquired a new position in Pharvaris in the third quarter valued at approximately $106,000. Geode Capital Management LLC boosted its holdings in Pharvaris by 18.4% in the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after purchasing an additional 5,753 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Pharvaris in the third quarter valued at approximately $57,000. Jane Street Group LLC acquired a new stake in shares of Pharvaris in the third quarter valued at approximately $526,000. Finally, Sphera Funds Management LTD. boosted its holdings in shares of Pharvaris by 8.9% in the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock valued at $8,136,000 after acquiring an additional 36,027 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.